ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-04-19 21:00 |
Abivax : résultats annuels 2022 et point d’avancement sur l’activité
|
French | 324.8 KB | ||
| 2023-04-19 21:00 |
Abivax reports 2022 financial results and operations update
|
English | 50.7 KB | ||
| 2023-04-18 18:00 |
Michael Ferguson est nommé Directeur Commercial d’Abivax
|
French | 213.0 KB | ||
| 2023-04-18 18:00 |
Abivax appoints Michael Ferguson as Chief Commerical Officer
|
English | 13.0 KB | ||
| 2023-04-17 18:00 |
Abivax annonce les résultats d’efficacité et de tolérance d’obefazimod après de…
|
French | 236.9 KB | ||
| 2023-04-17 18:00 |
Abivax reports two-year efficacy and safety data of obefazimod phase 2b mainten…
|
English | 20.2 KB | ||
| 2023-04-05 19:30 |
Marc de Garidel est nommé Directeur Général et Président par intérim du Conseil…
|
French | 222.0 KB | ||
| 2023-04-05 19:30 |
Abivax appoints Marc de Garidel as Chief Executive Officer and Interim Board Ch…
|
English | 13.9 KB | ||
| 2023-03-30 11:09 |
Franchissement de seuil et déclaration d'intention
|
French | 273.2 KB | ||
| 2023-03-29 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 285.8 KB | ||
| 2023-03-16 18:30 |
Abivax actualise son calendrier de communication financière 2023
|
French | 179.2 KB | ||
| 2023-03-16 18:30 |
Abivax adjusts its 2023 Financial Communication Calendar
|
English | 11.3 KB | ||
| 2023-03-14 15:43 |
Franchissement de seuils
|
French | 199.9 KB | ||
| 2023-03-14 15:22 |
Franchissements de seuil et déclaration d'intention
|
French | 274.8 KB | ||
| 2023-03-13 12:00 |
Abivax ne détient pas de liquidités ni de dépôts auprès de SVB ou d’autres inst…
|
French | 129.1 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
